Curium Completes Patient Enrollment of Phase 3 ECLIPSE Trial Ahead of Schedule
November 23, 2023 07:47 ET
|
Curium
Curium, a global leader in nuclear medicine, announced today the successful completion of patient enrollment in the pivotal Phase 3 ECLIPSE trial.
Curium Announces First Patients in Europe Injected With PYLCLARI® – an Innovative 18F-PSMA Pet Tracer Indicated in Patients With Prostate Cancer
November 16, 2023 05:14 ET
|
Curium
PARIS, Nov. 16, 2023 (GLOBE NEWSWIRE) -- Curium, a world leader in nuclear medicine, announced today that in partnership with its exclusive distributor SYN Innovation Laboratories in Greece, the...
Η CURIUM ΑΝΑΚΟΙΝΏΝΕΙ ΌΤΙ ΟΙ ΠΡΏΤΟΙ ΑΣΘΕΝΕΊΣ ΣΤΗΝ ΕΛΛΆΔΑ ΈΛΑΒΑΝ ΈΝΕΣΗ ΜΕ PYLCLARI® - ΈΝΑΝ ΚΑΙΝΟΤΌΜΟ ΙΧΝΗΘΈΤΗ PET 18F-PSMA ΠΟΥ ΕΝΔΕΊΚΝΥΤΑΙ ΣΕ ΑΣΘΕΝΕΊΣ ΜΕ ΚΑΡΚΊΝΟ ΤΟΥ ΠΡΟΣΤΆΤΗ
November 16, 2023 05:14 ET
|
Curium US LLC
ΠΑΡΙΣΙ, Nov. 16, 2023 (GLOBE NEWSWIRE) -- Η Curium, παγκόσμιος ηγέτης στην πυρηνική ιατρική, ανακοίνωσε σήμερα ότι σε συνεργασία με τον αποκλειστικό διανομέα της SYN Innovation Laboratories στην...
Curium and PIUR IMAGING Announce Thyroid Imaging Partnership in Germany to Enable Tomographic 3D Ultrasound Solutions
October 25, 2023 07:33 ET
|
Curium
BERLIN, Oct. 25, 2023 (GLOBE NEWSWIRE) -- Curium, a world leader in nuclear medicine, and PIUR IMAGING, a European medical device company at the forefront of pioneering tomographic 3D ultrasound...
CURIUM UND PIUR IMAGING KÜNDIGEN EINE PARTNERSCHAFT FÜR DIE SCHILDDRÜSENBILDGEBUNG IN DEUTSCHLAND AN, UM TOMOGRAPHISCHE 3D-ULTRASCHALLÖSUNGEN ZU ERMÖGLICHEN
October 25, 2023 07:33 ET
|
Curium
BERLIN, Oct. 25, 2023 (GLOBE NEWSWIRE) -- Curium, ein weltweit führendes Unternehmen in der Nuklearmedizin, und PIUR IMAGING, ein europäisches Medizintechnikunternehmen, das bei der Entwicklung von...
Curium Announces Exclusive Distribution Agreement in Switzerland with b.e. Imaging for PYLCLARI™, an Innovative 18F-PSMA Pet Tracer Indicated in Adults with Prostate Cancer
September 07, 2023 04:25 ET
|
Curium
PARIS, Sept. 07, 2023 (GLOBE NEWSWIRE) -- Curium, a world leader in nuclear medicine, announced today that it has entered into an exclusive rights agreement with b.e. Imaging, for the distribution...
Curium Announces Achievement of Co-Primary Endpoints in Phase 2 of Its Phase 1/2 SOLAR Clinical Trial Imaging Men With Histologically-Proven Prostate Cancer Using Copper Cu 64 PSMA I&T
August 15, 2023 10:50 ET
|
Curium
PARIS, Aug. 15, 2023 (GLOBE NEWSWIRE) -- Curium, a world leader in nuclear medicine, announced today the positive results of the multi-center, open-label, Phase 2 SOLAR study of Copper Cu 64 PSMA...
Curium Receives Marketing Authorization in the EU for PYLCLARI™, an Innovative 18F-PSMA PET Tracer Indicated in Adults With Prostate Cancer
July 28, 2023 06:12 ET
|
Curium
PARIS, July 28, 2023 (GLOBE NEWSWIRE) -- Curium, a world leader in nuclear medicine, announced that the European Commission has granted marketing authorization for PYLCLARI™ (INN: Piflufolastat...
Curium Announces License and Development Agreement With Lantheus for AI-Based PSMA PET Software in Europe
July 25, 2023 06:06 ET
|
Curium
Builds on existing collaboration between Curium and Lantheus for prostate cancer PSMA-targeted PET imagingDeep-learning platform for standardization of comprehensive reporting in Europe PARIS, July ...
Curium Announces Publication of [18F]DCFPyL Versus [18F]Fluoromethylcholine Results From European Phase III Study (PYTHON Trial)
July 21, 2023 03:30 ET
|
Curium
PARIS, July 21, 2023 (GLOBE NEWSWIRE) -- Curium, a world leader in nuclear medicine, announced today the publication of the results of its European, multicenter, prospective cross-over clinical...